Alivus Life Sciences Q3 Net Profit Rises 9.7% YoY to ₹150.26 Cr; Revenue up 4.8%
Alivus Life Sciences reported a steady performance for Q3 FY26, with revenue from operations growing 4.8% YoY to ₹672.89 crore. Net profit increased by 9.7% YoY to ₹150.26 crore, despite a one-time exceptional charge of ₹25.66 crore due to the implementation of new statutory labour codes. On a sequential basis, the company showed strong recovery with revenue and PAT growing by 14.4% and 15.5% respectively compared to Q2 FY26. The core API business remains the sole driver of growth, maintaining healthy margins.
முக்கிய அம்சங்கள்
Revenue from operations grew 14.4% QoQ to ₹6,728.89 million.
Net profit stood at ₹1,502.61 million, up from ₹1,369.60 million in the same quarter last year.
Reported an exceptional item of ₹256.57 million for statutory impacts of new labour codes (gratuity and absences).
Basic EPS improved to ₹12.25 from ₹11.18 YoY.
Total income for the nine-month period reached ₹19,003.48 million compared to ₹17,618.21 million last year.
👀 கவனிக்க வேண்டியவை
The company shows resilient growth and strong sequential recovery in its core API business. Investors should maintain a positive outlook as the operational performance remains robust despite the one-time regulatory-driven cost adjustment.
